Shares of Transenterix Inc (NASDAQ:TRXC) have been assigned an average broker rating score of 1.67 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. Transenterix’s rating score has improved by 16.5% in the last three months as a result of various analysts’ ratings changes.

Brokers have set a one year consensus price objective of $3.38 for the company and are expecting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned Transenterix an industry rank of 110 out of 265 based on the ratings given to its competitors.

A number of analysts recently weighed in on TRXC shares. B. Riley lowered shares of Transenterix to a “neutral” rating and set a $0.70 price objective for the company. in a research note on Tuesday, May 16th. Zacks Investment Research raised shares of Transenterix from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research report on Thursday, July 13th.

COPYRIGHT VIOLATION NOTICE: “Transenterix Inc (TRXC) Given $3.38 Consensus Target Price by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/09/transenterix-inc-trxc-given-3-38-consensus-target-price-by-analysts.html.

Shares of Transenterix (TRXC) opened at 1.12 on Friday. Transenterix has a 52-week low of $0.45 and a 52-week high of $2.33. The stock has a 50 day moving average of $0.77 and a 200 day moving average of $0.84. The stock’s market capitalization is $166.36 million.

Several hedge funds have recently added to or reduced their stakes in TRXC. Goldman Sachs Group Inc. lifted its position in shares of Transenterix by 7,137.7% during the second quarter. Goldman Sachs Group Inc. now owns 1,203,199 shares of the company’s stock valued at $854,000 after buying an additional 1,186,575 shares during the last quarter. UBS Oconnor LLC purchased a new stake in shares of Transenterix during the second quarter valued at about $390,000. LMR Partners LLP purchased a new stake in shares of Transenterix during the second quarter valued at about $189,000. Global X Management Co. LLC lifted its position in shares of Transenterix by 238.3% during the second quarter. Global X Management Co. LLC now owns 331,075 shares of the company’s stock valued at $235,000 after buying an additional 233,213 shares during the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Transenterix by 17.1% during the second quarter. Royal Bank of Canada now owns 418,867 shares of the company’s stock valued at $298,000 after buying an additional 61,034 shares during the last quarter.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Get a free copy of the Zacks research report on Transenterix (TRXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.